David Fabrizio

foundation medicine

37H指数

210论文数

1.6W被引数

收录论文 37

发表时间

Intratumoral heterogeneity and immunotherapy resistance: clinical implications 肿瘤内异质性与免疫治疗耐药性：临床意义

Annals of Oncology

IF65.4

2025-11-05

PREAI

B.P. Keenan; M. Yadav; G. Ansstas; D. Fabrizio; K. Murugesan; M. Montesion; D.Guha Niyogi; I. Mellman; I. Melero

Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages

DIAGNOSTICS

IF3.3

2024-04-27

OAAI

McKelvey, Brittany A.; Andrews, Hillary S.; Baehner, Frederick L.; Chen, James; Espenschied, Carin R.; Fabrizio, David; Gorton, Vanessa; Gould, Claire; Guinney, Justin; Jones, Greg; Lv, Xiangyang; Nahorski, Michael S.; Palomares, Melanie R.; Pestano, Gary A.; Sausen, Mark; Silk, Alain; Zhang, Nicole; Zhang, Zhihong; Stewart, Mark D.; Allen, Jeff D.

Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project (vol 32, pg 1626, 2021)

ANNALS OF ONCOLOGY

IF65.4

2024-01-01

OAAI

Vega, D. M.; Yee, L. M.; McShane, L. M.; Williams, P. M.; Chen, L.; Vilimas, T.; Fabrizio, D.; Funari, V.; Newberg, J.; Bruce, L. K.; Chen, S-J; Baden, J.; Barrett, J. Carl; Beer, P.; Butler, M.; Cheng, J-H; Conroy, J.; Cyanam, D.; Eyring, K.; Garcia, E.; Green, G.; Gregersen, V. R.; Hellmann, M. D.; Keefer, L. A.; Lasiter, L.; Lazar, A. J.; Li, M. -C; MacConaill, L. E.; Meier, K.; Mellert, H.; Pabla, S.; Pallavajjalla, A.; Pestano, G.; Salgado, R.; Samara, R.; Sokol, E. S.; Stafford, P.; Budczies, J.; Stenzinger, A.; Tom, W.; Valkenburg, K. C.; Wang, X. Z.; Weigman, V.; Xie, M.; Xie, Q.; Zehir, A.; Zhao, C.; Zhao, Y.; Stewart, M. D.; Allen, J.

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer 基于循环肿瘤DNA的纵向模型与转移性非小细胞肺癌的生存相关

NATURE MEDICINE

IF50

2023-03-16

OAAI

Assaf, Zoe June F.; Zou, Wei; Fine, Alexander D.; Socinski, Mark A.; Young, Amanda; Lipson, Doron; Freidin, Jonathan F.; Kennedy, Mark; Polisecki, Eliana; Nishio, Makoto; Fabrizio, David; Oxnard, Geoffrey R.; Cummings, Craig; Rode, Anja; Reck, Martin; Patil, Namrata S.; Lee, Mark; Shames, David S.; Schulze, Katja

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors KRAS改变癌症的全面泛癌症基因组景观和实体瘤的现实世界结果

NPJ PRECISION ONCOLOGY

IF8

2022-12-09

OAAI

Lee, Jessica K.; Sivakumar, Smruthy; Schrock, Alexa B.; Madison, Russell; Fabrizio, David; Gjoerup, Ole; Ross, Jeffrey S.; Frampton, Garrett M.; Napalkov, Pavel; Montesion, Meagan; Schutzman, Jennifer L.; Ye, Xin; Hegde, Priti S.; Nagasaka, Misako; Oxnard, Geoffrey R.; Sokol, Ethan S.; Ou, Sai-Hong Ignatius; Shi, Zhen

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial 阿特珠单抗与化疗治疗高血液肿瘤突变负荷的晚期或转移性NSCLC: BFAST队列C随机3期试验的初步分析

NATURE MEDICINE

IF50

2022-08-22

OAAI

Peters, Solange; Dziadziuszko, Rafal; Morabito, Alessandro; Felip, Enriqueta; Gadgeel, Shirish M.; Cheema, Parneet; Cobo, Manuel; Andric, Zoran; Barrios, Carlos H.; Yamaguchi, Masafumi; Dansin, Eric; Danchaivijitr, Pongwut; Johnson, Melissa; Novello, Silvia; Mathisen, Michael S.; Shagan, Sarah M.; Schleifman, Erica; Wang, Jin; Yan, Mark; Mocci, Simonetta; Voong, David; Fabrizio, David A.; Shames, David S.; Riehl, Todd; Gandara, David R.; Mok, Tony

Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy

NPJ PRECISION ONCOLOGY

IF8

2022-06-23

OAAI

Ebot, Ericka M.; Duncan, Daniel L.; Tolba, Khaled; Fabrizio, David; Frampton, Garrett M.; Comment, Leah A.; Albacker, Lee A.

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

NATURE MEDICINE

IF50

2022-04-14

OAAI

Kim, Edward S.; Velcheti, Vamsidhar; Mekhail, Tarek; Yun, Cindy; Shagan, Sarah M.; Hu, Sylvia; Chaes, Young Kwang; Leal, Ticiana A.; Dowell, Jonathan E.; Tsai, Michaela L.; Dakhil, Christopher S. R.; Stella, Philip; Jin, Yanling; Shames, David S.; Schleifman, Erica; Fabrizio, David A.; Phan, See; Socinski, Mark A.

Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project

ANNALS OF ONCOLOGY

IF65.4

2021-12-01

OAAI

Vega, D. M.; Yee, L. M.; McShane, L. M.; Williams, P. M.; Chen, L.; Vilimas, T.; Fabrizio, D.; Funari, V.; Newberg, J.; Bruce, L. K.; Chen, S. -j.; Baden, J.; Barrett, J. Carl; Beer, P.; Butler, M.; Cheng, J. -h.; Conroy, J.; Cyanam, D.; Eyring, K.; Garcia, E.; Green, G.; Gregersen, V. R.; Hellmann, M. D.; Keefer, L. A.; Lasiter, L.; Lazar, A. J.; Li, M. -c.; MacConaill, L. E.; Meier, K.; Mellert, H.; Pabla, S.; Pallavajjalla, A.; Pestano, G.; Salgado, R.; Samara, R.; Sokol, E. S.; Stafford, P.; Budczies, J.; Stenzinger, A.; Tom, W.; Valkenburg, K. C.; Wang, X. Z.; Weigman, V.; Xie, M.; Xie, Q.; Zehir, A.; Zhao, C.; Zhao, Y.; Stewart, M. D.; Allen, J.

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population (vol 5, 69, 2021)

NPJ PRECISION ONCOLOGY

IF8

2021-09-17

OAAI

Westphalen, C. B.; Krebs, M. G.; Le Tourneau, C.; Sokol, E. S.; Maund, S. L.; Wilson, T. R.; Jin, D. X.; Newberg, J. Y.; Fabrizio, D.; Veronese, L.; Thomas, M.; de Braud, F.

Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN

ANNALS OF ONCOLOGY

IF65.4

2021-09-01

OAAI

Saori, M.; Nakamura, Y.; Sawada, K.; Horasawa, S.; Kadowaki, S.; Kato, K.; Ueno, M.; Oki, E.; Satoh, T.; Komatsu, Y.; Tukachinsky, H.; Lee, J.; Madison, R.; Sokol, E.; Pavlick, D.; Aiyer, A.; Fabrizio, D.; Venstrom, J.; Oxnard, G.; Yoshino, T.

Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab

ANNALS OF ONCOLOGY

IF65.4

2021-09-01

PREAI

Fabrizio, D.; Cristescu, R.; Albacker, L.; Snyder, A.; Ward, A.; Lunceford, J.; Aurora-Garg, D.; Jin, F.; Hopkins, J.; Rubin, E.; Hegde, P.

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

NPJ PRECISION ONCOLOGY

IF8

2021-07-20

127

OAAI

Westphalen, C. B.; Krebs, M. G.; Le Tourneau, C.; Sokol, E. S.; Maund, S. L.; Wilson, T. R.; Jin, D. X.; Newberg, J. Y.; Fabrizio, D.; Veronese, L.; Thomas, M.; de Braud, F.

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inibitor Response 体细胞HLA I类丢失是免疫逃避的一种广泛机制，它完善了肿瘤突变负荷作为检查点免疫反应生物标志物的用途

CANCER DISCOVERY

IF33.3

2021-02-02

124

OAAI

Montesion, Meagan; Murugesan, Karthikeyan; Jin, Dexter X.; Sharaf, Radwa; Sanchez, Nora; Guria, Ameet; Minker, Max; Li, Gerald; Fisher, Virginia; Sokol, Ethan S.; Pavlick, Dean C.; Moore, Jay A.; Braly, Alan; Singal, Gaurav; Fabrizio, David; Comment, Leah A.; Rizvi, Naiyer A.; Alexander, Brian M.; Frampton, Garrett M.; Hegde, Priti S.; Albacker, Lee A.

Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors 识别和利用生物标志物预测对免疫检查点抑制剂的反应

AAPS JOURNAL

IF3.7

2020-10-14

PREAI

Gjoerup, Ole; Brown, Charlotte A.; Ross, Jeffrey S.; Huang, Richard S. P.; Schrock, Alexa; Creeden, James; Fabrizio, David; Tolba, Khaled

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naive Patients with Diverse Cancers

MOLECULAR CANCER THERAPEUTICS

IF5.5

2020-10-02

OAAI

Riviere, Paul; Goodman, Aaron M.; Okamura, Ryosuke; Barkauskas, Donald A.; Whitchurch, Theresa J.; Lee, Suzanna; Khalid, Noor; Collier, Rachel; Mareboina, Manvita; Frampton, Garrett M.; Fabrizio, David; Sharabi, Andrew B.; Kato, Shumei; Kurzrock, Razelle

Alignment of TMB measured on clinical samples: Phase IIB of the Friends of Cancer Research TMB Harmonization Project

CANCER RESEARCH

IF16.6

2020-08-15

PREAI

Merino, Diana M.; Yee, Laura M.; McShane, Lisa M.; Williams, P. Mickey; Vilimas, Tomas; Patidar, Rajesh; Barrett, J. Carl; Chen, Shu-Jen; Cheng, Jen-Hao; Conroy, Jeffrey M.; Cyanam, Dinesh; Eyring, Kenneth R.; Fabrizio, David A.; Funari, Vincent; Garcia, Elizabeth P.; Glenn, Sean T.; Gocke, Christopher D.; Gupta, Vikas; Haley, Lisa M.; Hellmann, Matthew D.; Keefer, Laurel; Keeler, Lauryn R.; Kennedy, Brett; Lazar, Alexander J.; MacConaill, Laura E.; Meier, Kristen L.; Papin, Arnaud; Rizvi, Naiyer A.; Sokol, Ethan; Stafford, Phillip; Thompson, John F.; Tom, Warren; Weigman, Victor J.; Xie, Mingchao; Zhao, Chen; Stewart, Mark D.; Allen, Jeff

Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2020-08-03

OAAI

Comment, Leah A.; Ward, Ashley F.; Schrock, Alexa B.; Fabrizio, David; Venstrom, Jeffrey M.; Hegde, Priti S.; Alexander, Brian M.

Clinical and analytic validation of FoundationOne CDx™ for NTRK fusion-positive solid tumors in patients treated with entrectinib

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-12-01

PREAI

Fabrizio, David; Milbury, Coren; Yip, Wai-Ki; Yilmazel, Bahar; Bai, Xiaobo; Liao, Juan; Smith, David; Burns, Christine; Vietz, Christine

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples

JOURNAL OF MOLECULAR DIAGNOSTICS

IF3.4

2019-11-01

173

OAAI

Trabucco, Sally E.; Gowen, Kyle; Maund, Sophia L.; Sanford, Eric; Fabrizio, David A.; Hall, Michael J.; Yakirevich, Evgeny; Gregg, Jeffrey P.; Stephens, Phil J.; Frampton, Garrett M.; Hegde, Priti S.; Miller, Vincent A.; Ross, Jeffrey S.; Hartmaier, Ryan J.; Huang, Shih-Min A.; Sun, James X.

研究方向